CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) — Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

Oral Presentations:

Poster Presentations:

About Solid Biosciences
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solid’s lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold.  For more information, please visit www.solidbio.com.

Contact:
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
[email protected] 
[email protected]